Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16760624 | 0.93 | BRD4 (0.70) | BRD4CREBBP | |
| SCHEMBL14723518 | 0.87 | BRD4 (0.78) | BRD4CREBBP | |
| SCHEMBL14722707 | 0.84 | BRD4 (0.77) | BRD4CREBBP | |
| SCHEMBL14723496 | 0.82 | BRD4 (0.80) | BRD4CREBBP | |
| SCHEMBL16760615 | 0.82 | BRD4 (0.73) | BRD4CREBBP | |
| SCHEMBL14721529 | 0.82 | BRD4 (0.70) | BRD4CREBBP | |
| SCHEMBL14723566 | 0.82 | BRD4 (0.77) | BRD4CREBBP | |
| SCHEMBL14721322 | 0.81 | BRD4 (0.79) | BRD4CREBBP | |
| SCHEMBL14723089 | 0.81 | BRD4 (0.79) | BRD4CREBBP | |
| SCHEMBL14722824 | 0.80 | BRD4 (1.00) | BRD4CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013027168-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | PFIZER INC. (US) | 2013-02-28 | — | — | WO | claimed |
| US-20170122958-A1 | Enzymes Functional Probes | UNIVERSITY OF DUNDEE (GB) | 2017-05-04 | — | — | US | disclosed |
| US-20170122958-A1 | Enzymes Functional Probes | UNIVERSITY OF DUNDEE (GB) | 2017-05-04 | — | — | US | disclosed |
| US-20170122958-A1 | Enzymes Functional Probes | UNIVERSITY OF DUNDEE (GB) | 2017-05-04 | — | — | US | disclosed |
| EP-3074514-A2 | ENZYMES FUNCTIONAL PROBES | University Of Dundee (GB) | 2016-10-05 | — | — | EP | disclosed |
| WO-2015079259-A2 | ENZYMES FUNCTIONAL PROBES | UNIVERSITY OF DUNDEE (GB) | 2015-06-04 | — | — | WO | disclosed |
| WO-2015079259-A2 | ENZYMES FUNCTIONAL PROBES | UNIVERSITY OF DUNDEE (GB) | 2015-06-04 | — | — | WO | disclosed |
| WO-2013027168-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | PFIZER INC. (US) | 2013-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170122958-A1 | Enzymes Functional Probes | BRDT, BRD1, BRD3 | BRD4 6/4885CREBBP 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.